GR3022554T3 - Novel deoxygalactonojirimycin derivatives - Google Patents

Novel deoxygalactonojirimycin derivatives

Info

Publication number
GR3022554T3
GR3022554T3 GR970400244T GR970400244T GR3022554T3 GR 3022554 T3 GR3022554 T3 GR 3022554T3 GR 970400244 T GR970400244 T GR 970400244T GR 970400244 T GR970400244 T GR 970400244T GR 3022554 T3 GR3022554 T3 GR 3022554T3
Authority
GR
Greece
Prior art keywords
novel
deoxygalactonojirimycin
derivatives
deoxygalactonojirimycin derivatives
alkyl
Prior art date
Application number
GR970400244T
Other languages
Greek (el)
English (en)
Inventor
Frances M Platt
Gabrielle R Neises
Raymond A Dwek
Terry D Butters
Original Assignee
Searle & Co
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/061,645 external-priority patent/US5399567A/en
Application filed by Searle & Co, Monsanto Co filed Critical Searle & Co
Publication of GR3022554T3 publication Critical patent/GR3022554T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
GR970400244T 1993-05-13 1997-02-12 Novel deoxygalactonojirimycin derivatives GR3022554T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/061,645 US5399567A (en) 1993-05-13 1993-05-13 Method of treating cholera
US08/102,654 US6291657B1 (en) 1993-05-13 1993-08-05 Deoxygalactonojirimycin derivatives
PCT/US1994/004974 WO1994026714A1 (en) 1993-05-13 1994-05-11 Novel deoxygalactonojirimycin derivatives

Publications (1)

Publication Number Publication Date
GR3022554T3 true GR3022554T3 (en) 1997-05-31

Family

ID=26741316

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970400244T GR3022554T3 (en) 1993-05-13 1997-02-12 Novel deoxygalactonojirimycin derivatives

Country Status (11)

Country Link
US (3) US6291657B1 (OSRAM)
EP (1) EP0698012B1 (OSRAM)
JP (1) JP3636363B2 (OSRAM)
AT (1) ATE148456T1 (OSRAM)
AU (1) AU6783294A (OSRAM)
CA (1) CA2159988C (OSRAM)
DE (1) DE69401658T2 (OSRAM)
DK (1) DK0698012T3 (OSRAM)
ES (1) ES2097653T3 (OSRAM)
GR (1) GR3022554T3 (OSRAM)
WO (1) WO1994026714A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖n−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
JP2003506406A (ja) 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード 長鎖n−アルキル化合物およびそのオキサ誘導体
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
US7994198B2 (en) 2002-07-17 2011-08-09 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
WO2004007453A1 (en) 2002-07-17 2004-01-22 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
GB0229476D0 (en) * 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
ES2619353T3 (es) 2003-01-31 2017-06-26 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
CN1906162B (zh) * 2003-11-12 2012-05-23 阿米库斯治疗学公司 用于治疗戈谢病的羟基哌啶衍生物
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
ES2572148T3 (es) 2005-05-17 2016-05-30 Amicus Therapeutics Inc Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
CA2719567A1 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
CN102427804A (zh) * 2009-03-27 2012-04-25 牛津大学之校长及学者 降低胆固醇水平的脂质体
WO2010111711A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
CA2822493C (en) 2010-12-23 2018-11-20 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2014032187A1 (en) * 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
CN104918619B (zh) * 2013-01-09 2019-04-02 阿米库斯治疗学公司 稳定的肠胃外dnj组合物
US11306058B2 (en) 2017-06-01 2022-04-19 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
EP4034256B1 (en) 2019-09-25 2025-11-19 Assia Chemical Industries Ltd. Solid state forms of lucerastat salts and process for preparation thereof
WO2022132992A1 (en) 2020-12-16 2022-06-23 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
WO2025017212A1 (en) 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Udp-glucose ceramide glucosyltransferase synthase (ugcg) inhibitors in the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
WO1987003903A1 (en) 1985-12-23 1987-07-02 Fred Hutchinson Cancer Research Center Regulating retroviral replication, infection, and pathogenesis
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
EP0536402A4 (en) 1990-06-29 1993-05-12 Nippon Shinyaku Company, Limited Piperidine derivative
US5128347A (en) * 1990-10-18 1992-07-07 Monsanto Company Glycosidase inhibiting 1,4-dideoxy-4-fluoronojirimycin

Also Published As

Publication number Publication date
ATE148456T1 (de) 1997-02-15
WO1994026714A1 (en) 1994-11-24
US6291657B1 (en) 2001-09-18
DK0698012T3 (OSRAM) 1997-02-17
EP0698012B1 (en) 1997-01-29
DE69401658T2 (de) 1997-06-12
AU6783294A (en) 1994-12-12
US5786368A (en) 1998-07-28
JP3636363B2 (ja) 2005-04-06
CA2159988C (en) 2007-01-09
EP0698012A1 (en) 1996-02-28
JPH08510244A (ja) 1996-10-29
CA2159988A1 (en) 1994-11-24
DE69401658D1 (de) 1997-03-13
ES2097653T3 (es) 1997-04-01
US5580884A (en) 1996-12-03

Similar Documents

Publication Publication Date Title
DK0698012T3 (OSRAM)
ZA955466B (en) Stereochemical wortmannin derivatives
ZA976705B (en) Process for the synthesis of protected esters of (S)-3,4-dihydroxybutric acid.
GB2301106B (en) Synergistic stabilizer mixture
HU9302335D0 (en) 9-|(substituted glycyl)-amido¨-6-desmethyl-6-desoxy-tetracyclines
HU9302965D0 (en) Substituted benzyl amino-quinuclidine derivatives
GR3027657T3 (en) N-alkylthio polyamine derivatives as radioprotective agents
AU3744397A (en) Total synthesis of antitumor acylfulvenes
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
ZA858169B (en) New adamantanamine derivatives,processes for their preparation and drugs in which they are present
UA66866C2 (uk) Синтез морфолінових похідних
MX9801190A (es) Inhibidores de prolil endopeptidasa.
AP9400632A0 (en) Ether derivatives.
IL128951A0 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
GR1002598B (el) Παραγωγα επι-επιβατιδινης.
GB9220876D0 (en) Compounds useful in oleaginous compositions
HU906010D0 (en) New substituted alkyl-piperidine derivatives
ZA9811380B (OSRAM)
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
YU71400A (sh) Poboljšani postupak za pripremanje farmaceutski dragocenih derivata norbenzomorfana
MX9801130A (es) Tiamacrolidos.
PL342992A1 (en) New compounds
MX9603450A (es) Procedimiento para la obtencion de aminotriazolinas substituidas.
GB9516143D0 (en) Improved chemical synthesis
GR3029453T3 (en) NOVEL PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PLATELET CLYCOPROTEIN IIb/IIIa INHIBITORS